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ABSTRACT  Cathelicidins form a family of small host defense peptides distinct from another 
class of cationic antimicrobial peptides, the defensins. They are expressed as large precursor 
molecules with a highly conserved pro-domain known as the cathelin-like domain (CLD). CLDs 
have high degrees of sequence homology to cathelin, a protein isolated from pig leukocytes and 
belonging to the cystatin family of cysteine protease inhibitors. In this report, we describe for the 
first time the X-ray crystal structure of the human CLD (hCLD) of the sole human cathelicidin, 
LL-37. The structure of hCLD, determined at 1.93 Å resolution, shows the cystatin-like fold and 
is highly similar to the structure of the CLD of the pig cathelicidin, protegrin-3. We assayed the 
in vitro antibacterial activities of hCLD, LL-37 and the precursor form, pro-cathelicidin (also 
known as hCAP18), and we found that the unprocessed protein inhibited the growth of Gram-
negative bacteria with efficiencies comparable to the mature peptide, LL-37.  In addition, the 
antibacterial activity of LL-37 was not inhibited by hCLD intermolecularly, since exogenously 
added hCLD had no effect on the bactericidal activity of the mature peptide. hCLD itself lacked 
antimicrobial function and did not inhibit the cysteine protease, cathepsin L. Our results contrast 
with previous reports of hCLD activity. A comparative structural analysis between hCLD and the 
cysteine protease inhibitor stefin A showed why hCLD is unable to function as an inhibitor of 
cysteine proteases. In this respect, the cystatin scaffold represents an ancestral structural platform 
from which proteins evolved divergently, with some losing inhibitory functions. 
TEXT  Cathelicidin antimicrobial peptides (CAMPs) are major components of innate immunity, 
acting directly against microbial infections (1-3). As the most abundant host defense peptides, 
CAMPs are found in many mammals including primates, rodents, ungulates and rabbits (1). 
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Recently, the cathelicidin-like genes have also been identified in non-mammals including 
chickens, Atlantic salmon and hagfish (4-6). The family of CAMPs is highly heterogeneous and 
covers a wide range of peptides that vary in length, share low sequence similarity and display 
marked structural diversity (3, 7, 8). 
CAMPs are synthesized as precursors with a significantly larger (94-114 aa) and highly 
conserved N-terminal pro-domain known as the cathelin-like domain or CLD (9-15). The CLD 
shows high sequence homology to cathelin, a protein of 96 aa residues isolated from porcine 
neutrophils and classified initially into the cystatin family of cysteine protease inhibitors based 
on its inhibitory activity against cathepsin L (13, 14).  Due to low sequence similarities among 
C-terminal antimicrobial domains, the evolutionarily conserved CLD defines these peptides as 
belonging to the cathelicidin family (7, 16). The pro-forms of CAMPs, by definition, are 
considered to be storage forms and, as inactive precursors, require proteolytic processing to 
become biologically functional (11, 17-20). During the activation process, a specific enzyme 
removes the CLD and frees the C-terminal antimicrobial peptide to fulfill its cathelicidin 
function (3). 
Despite the abundance of mammalian CAMPs, only one CAMP is found in humans (17, 
21-23). Human cathelicidin is stored as a 16-kDa pro-form, pro-cathelicidin, in the secondary 
granules of neutrophils. Pro-cathelicidin is also known as human CAP18 (hCAP18) based on its 
close relationship to CAP18, a cationic antimicrobial protein of 18 kDa isolated from the rabbit 
(22, 23). Pro-cathelicidin consists of an N-terminal human CLD (hCLD) of 103 amino acid 
residues and the C-terminal cathelicidin peptide, LL-37, of 37 residues. Upon stimulation, pro-
cathelicidin is processed into hCLD and LL-37 by proteinase 3, a serine protease originating 
from azurophilic granules (17, 19). In addition to neutrophils, which are the major source of LL-
 4 
37, the cathelicidin gene is also expressed in various blood cell populations including monocytes 
and certain lymphocytes (24), in the squamous epithelial cells of the airways, intestine and 
vagina (25), in the epididymis and testis (26), and in keratinocytes in inflammatory skin diseases. 
The prostate-specific protease, gastricsin, has been identified to process pro-cathelicidin in 
seminal plasma into ALL-38, which contains an additional Ala residue at the N-terminus as 
compared to LL-37 (27, 28).   
The multiple roles of LL-37 in host immune defense have been studied extensively 
during the two decades since its discovery (7, 29, 30). LL-37 was initially recognized for its 
broad-spectrum antimicrobial activity against bacteria, fungi, and viral pathogens. Other 
biologically important functions of LL-37 were subsequently reported, including 
immunomodulatory and chemotactic properties, stimulation of angiogenesis, and LPS-
neutralizing activities (22, 29-31). Recently, the high-quality solution structure of LL-37 in 
dodecylphosphocholine (DPC) and sodium dodecyl sulfate (SDS) micelles has been determined 
using multi-dimensional NMR spectroscopy, showing an α-helical and amphipathic structure of 
LL-37 upon target membrane binding (32, 33). 
In contrast to LL-37, little is known about the biological functions, if any, of pro-
cathelicidin and hCLD despite the presence of high concentrations of pro-cathelicidin in many 
biological settings including human blood plasma (25, 34) and seminal plasma (26). In fact, pro-
cathelicidin is considered to be a storage form of LL-37 endowed with no biological activity (19, 
35). Recently, hCLD has been shown to inhibit cathepsin L activity in vitro and possess 
antibacterial activity comparable to that of LL-37 (35). It has been proposed that hCLD may 
possess dual functions strictly related to the LL-37 maturation process: (1) intramolecularly 
inhibiting the antimicrobial function of LL-37 prior to proteolytic processing (7, 17, 22), and (2) 
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contributing to host defense through direct antimicrobial and protease inhibitory activities upon 
proteolytic processing (35).   
In this report, we describe for the first time the X-ray crystal structure of the CLD of 
human cathelicidin determined at 1.93 Å resolution. The structure of hCLD shows the expected 
cystatin family fold and is highly similar to the structure of ProS – the CLD of the pig 
cathelicidin protegrin-3 and the only mammalian CLD studied so far by X-ray crystallography 
and NMR spectroscopy. However, we could not confirm the inhibitory activity of hCLD against 
cathepsin L or three strains of bacteria. Instead, we found that pro-cathelicidin is capable of 
killing Gram-negative bacteria in vitro with efficiency comparable to that of the mature 
cathelicidin peptide LL-37. 
MATERIALS AND METHODS 
Expression and purification of pro-cathelicidin The cDNA fragment coding for the 
human cathelicidin precursor protein was amplified using a forward primer, 5’-
CATATGCAGGTCCTCAGCTACAAGGAAGCT, paired with a reverse primer, 5’-
GGATCCCTAGGACTCTGTACGAGGTACAAGATT. The PCR product was ligated into 
the pCR2.1-TOPO vector (Invitrogen) and sequenced to verify the sequence. The correct insert 
was cloned in the NdeI/BamHI sites of the pET15b Vector (Novagen). The translation product 
consists of an N-terminal His6-Tag followed by a thrombin digestion site and the full-length pro-
cathelicidin sequence. A single colony of E. coli BL21(DE3) carrying the recombinant plasmid 
was used to initiate growth of a 50-ml overnight culture at 37°C in Luria-Bertani broth (LB) 
supplemented with ampicillin (100 μg/ml). Each culture was then diluted 1:100 into fresh LB 
medium and grown to A600 = 0.8 at 37°C when the expression was induced by the addition of 
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isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The cells were 
harvested 4 h after induction by centrifugation at 6,000g for 20 min and subjected to lysis with 
BugBuster® Protein Extraction Reagent (Novagen). His6-pro-cathelicidin protein was produced 
exclusively as inclusion bodies. The pellet (insoluble fraction) was separated by centrifugation at 
20,000 g at 4°C for 15 min and washed several times with 2% (v/v) Triton X-100, 50 mM Tris 
(pH 7.5), and then with 50 mM Tris, pH 7.5 alone. Finally, the insoluble aggregates were 
dissolved under denaturing conditions in the binding buffer (6 M GuHCl, 20 mM sodium 
phosphate buffer, pH 7.4) and loaded onto a 5 ml HiTrap Chelating HP column (GE Amersham) 
charged with Ni and equilibrated with the binding buffer. Weakly-bound proteins were removed 
with binding buffer supplemented with 50 mM imidazole and His6-pro-cathelicidin was eluted 
with binding buffer supplemented with 500 mM imidazole. The denatured His6- pro-cathelicidin 
solution was supplemented with dithiothreitol (DTT) to a final concentration of 20 mM and 
stirred for 20 min. Fully reduced His6-pro-cathelicidin was next precipitated under reducing 
conditions by overnight dialysis against 50 mM Tris-HCl, pH 8.4, 1 mM DTT. Insoluble His6-
pro-cathelicidin protein was separated by centrifugation at 20,000 g for 15 min, dissolved in 6 M 
GuHCl and subjected to overnight oxidative folding through thiol-disulfide shuffling in the 
presence of reduced (3 mM) and oxidized (0.3 mM) glutathione, in 1.5 M GuHCl, 50 mM Tris-
HCl, pH 8.4. The oxidized sample was purified by preparative C18 reversed phase liquid 
chromatography (RP-HPLC) on a Waters Delta Prep 600 system and freeze-dried. The His-tag 
was cleaved from the His6-pro-cathelicidin protein by thrombin, which specifically recognizes 
and cleaves a sequence located upstream of the pro-cathelicidin sequence, i.e., LVPR↓GSHM. 
The digestion was carried out in thrombin digestion buffer (150 mM of NaCl, 2.5 mM CaCl2 and 
20 mM Tris-HCl, pH 8.4) with 2.5 U of thrombin (Invitrogen)/mg of His6-pro-cathelicidin. The 
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cleavage proceeded to completion in 30 minutes and the full-length pro-cathelicidin was purified 
to homogeneity by RP-HPLC and subsequently lyophilized. Of note, the recombinant pro-
cathelicidin protein contained four extra amino acid residues (GSHM) at its N-terminus – part of 
the thrombin cleavage sequence 
Generation and purification of the hCLD and LL-37 hCLD and LL-37 were generated 
by enzymatic cleavage of pro-cathelicidin with proteinase 3. Briefly, lyophilized pro-cathelicidin 
(1mg) was dissolved in 0.1M HEPES, pH 7.5 and treated with 0.5 U Proteinase 3 (Elastin 
Products Company, Inc, USA) for 3-4 hours, at room temperature. The two desired products 
were separated by preparative RP-HPLC and purified to homogeneity. The purity and identity of 
pro-cathelicidin, hCLD and LL-37 preparations were confirmed by analytical RP-HPLC and 
electrospray ionization mass spectrometry (ESI-MS, Micromass ZQ-4000) (Figure 1). 
Crystallization and Data Collection The crystallization experiment was performed at 
room temperature using the hanging-drop vapor diffusion method. Drops were prepared by 
mixing 1 μl stock solution of hCLD at 10 mg/ml in water and 1 μl reservoir solution (0.1 M 
sodium HEPES pH 7.5, 0.2 M sodium citrate, 20% isopropanol). The best quality crystals were 
cryoprotected in a solution containing the reservoir solution and 25% glycerol, and flash-cooled 
with liquid nitrogen at 100K. The data were collected at Stanford Synchrotron Radiation 
Laboratory (Menlo Park, CA) (beamline 9-1) using an ADSC Quantum-315R CCD detector 
(Area Detector Systems Corp). The data were integrated with DENZO and scaled with 
SCALPACK using the HKL2000 package (36). Crystals of hCLD belonged to space group 
p21212 with unit cell dimensions of a=91.15 Å, b=57.99 Å, c=39.55 Å and two molecules of 
hCLD per asymmetric unit.  The data statistics are summarized in Table 1. 
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Structure Determination and Refinement The structure of hCLD was solved by molecular 
replacement with Phaser (37) from the CCP4 suite (38) using the CLD of protegrin-3 (PDB code 
1PFP, (39)) as a search model. The structure was refined with the program Refmac5 (40) and 
rebuilt using the program COOT (41). Final model statistics are shown in Table 1. The 
coordinates and structure factors have been deposited in the Protein Data Bank (PDB code). 
Ramachandran statistics were calculated with MolProbity (42) and all illustrations were prepared 
with the the PyMol Molecular Graphic suite (DeLano Scientific, San Carlos, CA, USA) 
Antimicrobial assays. Pro-cathelicidin, hCLD and LL-37 were tested for antibacterial 
activity against Escherichia coli ATCC 25922, Enterobacter aerogenes ATCC 13048 and 
Staphylococcus aureus ATCC 29213. Assays for antimicrobial activity were conducted using the 
96-well turbidimetric method known as virtual colony count (vCC), as previously described for 
α-defensins (43). Briefly, the bacteria (1×106 CFU/ml) were incubated at 37°C for 2h with 
various concentrations of protein. After addition of twice-concentrated Mueller-Hinton broth, the 
kinetics of bacterial growth were measured at 650 nm for 12 hours to determine the time 
necessary to reach a threshold change in optical density of 0.02.  Calibration experiments were 
conducted per Table 1 and Figure 2 of (43) using a Tecan infinite M1000 plate reader and 10 
mM phosphate buffer without supplementation by tryptic soy broth or other nutrients, resulting 
in a slope of -70.124 and y-intercept of 520.4 for E. coli, a slope of -65.315 and a y-intercept of 
484.3 for E. aerogenes, and a slope of -74.365 and y-intercept of 558.54 for S. aureus.  Because 
pro-cathelicidin and LL-37 in phosphate buffer were found to react with Mueller-Hinton broth to 
produce turbidity in the absence of cells, all four peptides were tested in the absence of cells.  
These background optical density experiments indicated that only pro-cathelicidin and LL-37 
turbidity fluctuated during the assay.  Except for one isolated point of the virtual survival plot at 
 9 
256 µg/mL (57 µM) caused by an anomalous S. aureus growth curve with a slightly slower 
growth rate than controls that was not corrected, LL-37 background turbidity only fluctuated 
significantly at 256 µg/mL, which completely inhibited growth in all eight other vCC 
experiments with the three strains.  This anomalous S. aureus growth curve could have been an 
experimental artifact resulting from cross-contamination leading to one or more cells adhering to 
the side of the well above the liquid until after the abrogation of LL-37 activity due to the 
addition of twice-concentrated Mueller Hinton broth to the well.  The 256-1 twofold dilution 
series of pro-cathelicidin was included on each microplate with buffer added in place of cells 
diluted in buffer, and optical density readings were subtracted from the experimental pro-
cathelicidin data exposed to cells at each 5-minute time point.  In addition, a data processing 
procedure called translocation was developed to correct for S. aureus growth curves that had 
reduced growth rates compared to the controls after the addition of Mueller-Hinton broth.  The 
threshold times at a change in optical density of 0.01 were calculated, and then the doubling 
times of each curve between 0.01 and 0.02 and standard deviation (SD) were calculated.  Curves 
with doubling times more than 3xSD greater than the mean of the controls were corrected by the 
translocation procedure, which replaced absorbance readings after a change in optical density of 
0.001 from a representative average control curve from the calibration experiment.  All assays 
were carried out in triplicate, except for hCLD and the lower concentration range of pro-
cathelicidin (diluted twofold from 128 to 0.5 µg/mL), which were assayed in duplicate. Some 
points on the virtual survival plot represent less than triplicate or duplicate results, as explained 
in the Table ST1.  Human α-defensin 1 (HNP1) was used as a positive control. The virtual LD50 
(vLD50), vLD90, vLD99 and vLD99.9 were reported as the protein concentrations that resulted in 
virtual survival rates of 0.5, 0.1, 0.01 and 0.001, respectively. 
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Enzyme inhibition assays A kinetic assay with fluorogenic substrates was used to 
determine the inhibitory activity of pro-cathelicidin, hCLD and LL-37 against human liver 
cathepsin L (Calbiochem, CA), as described earlier for the inhibition of the cysteine proteinases 
by cystatins (44). In brief, the enzyme (0.1 mU) was incubated for 2 min at 30°C with increasing 
concentrations (1 - 1000 nM) of pro-cathelicidin, hCLD and LL-37 in 0.1 M acetate buffer, pH 
5.5, 1 mM EDTA, 1 mM DTT, 0.1% Brij 35, followed by the addition of Z-Phe-Arg-AMC 
(where Z stands for benzyloxycarbonyl and AMC for 7-amino-4-methylcoumarin) to a final 
concentration of 20 µM. The fluorescence increase due to substrate cleavage was measured 
continuously for 20 min at excitation and emission wavelengths of 360 and 460 nm, respectively, 
using a Varian (Cary) Eclipse fluorescence spectrophotometer accessorized with a Cary Eclipse 
microplate reader. Human urine cystatin C was used as a positive control.  
RESULTS 
Protein preparation.  Pro-cathelicidin (140 aa) with an N-terminal His6Tag (in the 
pET15b expression vector) was expressed in E. coli as an insoluble protein and purified under 
denaturing conditions by immobilized nickel affinity chromatography. His6-tagged pro-
cathelicidin was fully reduced with DTT and reoxidized through thiol-disulfide shuffling in the 
presence of reduced and oxidized glutathione. Oxidative folding resulted in one major peak on 
analytical C18 RP-HPLC, which corresponds to the oxidized product with an observed molecular 
mass of 18175.9 Da (the expected value was 18175.6 Da, calculated on the basis of the average 
isotope compositions). The His6Tag was removed by thrombin cleavage and recombinant pro-
cathelicidin was purified to homogeneity by RP-HPLC. Quantitative cleavage was achieved 
within 30 min of incubation at room temperature, and nonspecific cleavage or further 
degradation of the desired product was not observed. The molecular mass of the cleaved product 
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was determined to be 16424.5 Da, in agreement with the calculated value of 16424.7 Da (Figure 
1). Biosynthesis on a one-liter culture scale typically yielded 3 mg of highly pure and correctly 
folded protein. 
Proteinase 3 is the processing enzyme of pro-cathelicidin in vivo.  It recognizes with high 
specificity a cleavage site within the pro-cathelicidin sequence (between Ala133 and Leu134) to 
generate hCLD (residues 31-133) and LL-37 (residues 134-170) (19). We treated recombinant 
pro-cathelicidin with proteinase 3 and, as expected, two chromatographically distinct species 
corresponding to hCLD and LL-37 were recovered. The two desired products were purified by 
RP-HPLC to homogeneity, and their molecular masses were ascertained by ESI-MS (Figure 1). 
For hCLD, its determined molecular mass of 11949.2 Da was in agreement with the expected 
value of 11949.4 Da calculated from the average isotopic compositions of hCLD; for LL-37, its 
determined molecular mass of 4492.9 Da also agreed with its theoretical value of 4493.3 Da. 
hCLD adopts the cystatin-like structural fold.  The crystal structure of hCLD was 
determined in space group P21212 and refined to 1.93 Å resolution (Table 1, Figure 2 and S1). 
The final model consists of two hCLD molecules in one asymmetric unit, both missing Pro65 
located in the L1 loop region. In molecule A the four extra amino acid residues as part of the 
His6Tag were assigned as -3 (Gly), -2 (Ser), -1 (His) and 0 (Met). The two hCLD molecules 
present in the asymmetric unit could be aligned with a root-mean-square (rms) deviation value of 
0.61 Å for 95 Cα atoms (Figure S1). The structure was refined to a final Rcrys of 19.6% and an 
Rfree of 24.9% with all non-glycine and non-proline residues falling in the most favored or 
additionally allowed regions of the Ramachandran plot (Table 1). 
Figure 2A shows the molecule of hCLD. It adopts a cystatin-like fold (45, 46) and 
contains a compact core formed by a twisted four-stranded antiparallel β-sheet and a long N-
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terminal α-helix packing against each other. From the top, the core is flanked by flexible loops 
L1 (connecting β1 to β2) and L2 (connecting β3 to β4), and from the bottom, by an appending 
domain (connecting β2 to β3) consisting of a short 310-helix (Pro94-Glu95-Asp96) and two β turns 
(Arg88-Thr89 and Lys101-Asp102). This well-defined hCLD structure is stabilized by the Cys86-
Cys97 disulfide bond, which additionally connects the appending domain to the β2-strand and the 
core. The second disulfide bond Cys108-Cys125 is formed within the core and connects the β3 and 
β4 strands. 
The hCLD structure shows remarkable similarity to ProS, the only other CLD protein 
studied so far by X-ray crystallography and NMR spectroscopy (47-49). hCLD and ProS share 
66% sequence identity and, as shown in Figure 2B, their overall crystal structures are highly 
similar, with a root-mean-square deviation (rmsd) of 0.88Å for 81 Cα atom pairs (as compared 
with 1KWI) (47). Comparison of the distribution of secondary structure elements in both 
proteins confirms almost identical global folds and reveals only minor differences in the length 
of the main α-helix and the β4 strand. In fact, both ends of the β4 strand show the largest rmsd 
for corresponding Cα atoms (Figure 2B).  
Of note, the crystal structure of ProS lacks the L1 and L2 loops due to poorly defined 
electron density (47). We were able to resolve the conformation of the L2 loop in two hCLD 
molecules present in the asymmetric unit, which adopts a hydrogen-bonded tight turn spanning 
residues Gln116-Ala117-Arg118 (Figure 3). Comparison of the hCLD crystal structure and a 
solution structure of ProS ((49), rmsd of 1.1 Ǻ) shows a lack of such a turn in the highly mobile 
and unstructured L2 loop region of ProS. Analysis of the crystal contacts reveals that the Gln116-
Arg118 region of hCLD is partially constrained by intermolecular contacts. Thus, the L2 loop 
structure seen in hCLD may only partially represent a native conformation. 
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hCLD does not inhibit cathepsin L.  Recently, Zaiou et al. (35) and Zhu at al.(50) have 
reported intriguing results of cysteine proteinase inhibitory activities of human and porcine 
CLDs. Recombinant hCLD and ProS were reported to inhibit and activate cathepsin L, 
respectively. In light of these paradoxical reports, we tested the inhibition of human liver 
cathepsin L by our recombinant hCLD protein using the same protocol as described earlier for 
kinetic measurements of inhibitory activity of cystatins against cysteine proteases (44), and we 
failed to replicate these findings. 
We incubated cathepsin L (0.1 mU) for 2 min at 30°C with increasing concentrations of 
hCLD (from 0 to 1,000 nM) followed by addition of the fluorescent substrate Z-Phe-Arg-AMC, 
and the enzymatic reaction was kinetically monitored over a period of 20 min. As shown in 
Figure 4A, hCLD had little effect on cathepsin L activity at concentrations of up to 1,000 nM, 
while 10 nM of human urine cystatin C nearly quantitatively inhibited this protease under 
identical conditions. Since weak inhibitory activity against cathepsin L has been reported earlier 
for bovine cathelicidins ProBac5 (51, 52), ProBac7 and proBMP-28 (52), we also tested 
cathepsin L inhibition by human pro-cathelicidin and the LL-37 peptide. Indeed, pro-cathelicidin 
and LL-37 showed similarly weak but dose-dependent inhibition of cathepsin L at concentrations 
above 10 nM (Figure 4B). At the highest concentration used (1,000 nM), over 50% inhibition of 
protease activity was observed for pro-cathelicidin and LL-37. Since hCLD was inactive against 
cathepsin L, inhibition of cathepsin L by pro-cathelicidin and LL-37 likely resulted from the C-
terminal cathelicidin domain. 
hCLD shows no antibacterial activity.  Zaiou et al reported that recombinant hCLD 
protein was bactericidal when tested in a radial diffusion assay and a standard liquid phase AMP 
test (35). At concentrations ranging from 16 to 32 µM, hCLD was shown to kill E. coli and S. 
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aureus strains efficiently whereas pro-cathelicidin and mature LL-37 were inactive against S. 
aureus (35). These findings were surprising in light of the fact that LL-37 has been widely 
reported as a potent bactericidal peptide that acts effectively against both Gram-positive and 
Gram-negative strains of bacteria (30, 53, 54). We were therefore motivated to test the 
antibacterial activity of pro-cathelicidin, hCLD and LL-37 against E. coli and E. aerogenes 
(Gram-negative) and S. aureus (Gram-positive) using the previously established vCC 
turbidimetric method (43). To verify the vCC results, we also conducted an antibacterial assay 
using traditional colony count methods in the same 10 mM phosphate buffer used as the vCC 
experiment, and with the same 2-hour incubation time.  The α-defensin human neutrophil peptide 
1 (HNP1) was used as a positive control, and the data are shown in Figure 5A-C and S2 and 
Table ST1 and ST2.  
As expected, and consistent with previously reported data (30, 53, 54), LL-37 displayed 
potent antibacterial activity, and LL-37 was more potent than HNP1 against the tested bacteria in 
the region of the virtual lethal doses.  Importantly, the precursor protein pro-cathelicidin also 
efficiently inhibited the growth of two Gram-negative strains tested, E. coli and E. aerogenes, 
with similar potency (Figure 5A-C and Table ST1). Apparently, hCLD intramolecularly does 
not abrogate the antibacterial action of LL-37 except in the case of the Gram-positive S. aureus.  
Compared to other cathelicidins, our results with human pro-cathelicidin are distinct in that other 
members of the family are inactive before proteolytic processing.  In this respect, human pro-
cathelicidin may be an exception to the rule.  In sharp contrast, no antibacterial activity was 
detected for the hCLD protein even at the highest concentration used (60 µM). We confirmed 
our findings on pro-cathelicidin, hCLD and LL-37 with respect to their anti-E. coli activity or 
lack thereof using the standard radial diffusion method (55) and a lawn-spotting assay in a 
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second laboratory. As shown in Figure S3 and S4, while LL-37 and pro-cathelicidin showed 
dose-dependent inhibition of the growth of E. coli colonies, hCLD was completely inactive at the 
highest concentration tested (50 µM).  In addition, the traditional colony count results supported 
vCC qualitatively (Figure S2 and Table ST2).  HNP1 activity at high concentrations was greater 
in the vCC assay than the colony count assay, indicating that vCC measures lag times in addition 
to bacteriostatic growth inhibition and/or bactericidal killing, as initially reported (43). 
hCLD does not inhibit LL-37.  Human α-defensins are synthesized in vivo as inactive 
precursors, and defensin activation requires proteolytic removal of the N-terminal pro-domains 
(56). The pro-domains functionally neutralize defensin activity through both intramolecular and 
intermolecular interactions with defensins (55, 57). To better understand the functional aspects of 
the hCLD in relation to LL-37 in pro-cathelicidin, we tested the ability of different 
concentrations of hCLD to inhibit the anti-E. coli activity of LL-37 at the LD90 concentration of 
1.4 µM. As shown in (Figure 5D), no decrease of antibacterial activity was observed across the 
entire concentration range (up to 60 µM), demonstrating that exogenously added hCLD does not 
inhibit the antibacterial activity of the mature LL-37 peptide. 
A high degree of genetic similarity of the cathelin-like motif of cathelicidins to the 
cystatin family of protease inhibitors suggested that CLDs may act as protease inhibitors as well 
(12, 15, 21). Cathelin, a 96-residue peptide isolated from porcine neutrophils and sharing about 
70% identity with CLDs, initially was shown to inhibit cathepsin L. The inhibition was later 
ascribed to contamination by cystatins, calling into question the classification of porcine cathelin 
as a cysteine protease inhibitor (58). On the other hand, very recent studies suggested that human 
and porcine CLD may function as inhibitors or activators of cathepsin L, respectively (35, 50). 
Based on the modeled structures of hCLD and ProS in complex with cysteine protease, the 
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functional switch from inhibition to activation was attributed to the sequence variations in the L2 
loop region of human and porcine CLDs (35, 50, 59). Indeed, hCLDs and cystatins adopt similar 
three-dimentional structures, known as the cystatin-like fold, but our structural analysis does not 
confirm that hCLD is a functional inhibitor of cysteine proteases (60). First of all, hCLD and 
other CLDs differ substantially from cystatins at the protein sequence level.  hCLD lacks the 
functional residues that are involved in the specific binding of cysteine protease inhibitors to 
their targets, which are highly conserved among cystatins. It was shown that effective inhibitor 
binding requires presence of the GAP11, QVVAG57 and PW104 motifs (stefin B numbering) 
within the extended N-terminus and the L1 and L2 loops of cystatins, respectively (61-63). These 
motifs are not present in the hCLD sequence. The crystallographic studies of complexes formed 
by cysteine proteases and their cystatin inhibitors indicate that the cystatin-like fold of cystatins 
allows them to form a characteristic wedge-shaped structure with the N-terminal trunk and two 
hairpin loops at its narrow edge that fits into the substrate binding groove of the target protease 
(64-67). The extended N-terminus of cystatin occupies the S1 and S2 sites of the substrate 
binding area and occludes the catalytic Cys of the protease, whereas the L1 and L2 loops bind 
into the S1’ and S2’ sites, respectively. We aligned structurally the hCLD to the monomeric 
human Cystatin C in the unliganded state (PDB code: 3GAX, (68), Figure 6). In addition, since 
there is no available complex structure of Cystatin C with any of its targeted proteases, we 
superimposed the hCLD model to that of stefin A in the stefin A-cathepsin H complex (Figure 7, 
(67)). The structural similarities between hCLD and Cystatin C/stefin A are limited only to a 
common global fold, which clearly varies at the N-terminus as well as the L1 and L2 loop 
regions. As shown in Figure 2, the hCLD has a relatively short N-terminus with only four 
residues (the 30QVLS segment) proceeding the N-terminal α-helix. Although the hCLD protein 
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used in our studies has a four amino acid extension at the N-terminus as a remnant of the 
cleavage by thrombin (shown in grey in Figure 6), its presence should not have much effect on 
its conformation due to rigidifying interactions of the neighboring helix. The short N-terminus of 
hCLD faces away from the S1 and S2 sites which are occupied in the complex by the elongated 
N-terminal trunk of cystatin C/stefin A. These substantial differences are observed also for the 
conformation of the L1 and L2 loops of hCLD as compared to the equivalent hairpin loops of 
cystatin c/stefin A. hCLD, with its longer and ‘relaxed’ L1 loop and L2 loop constrained by the 
hydrogen-bonded turn at the top, is unable to form a characteristic wedge that could fit into the 
substrate-binding groove of cathepsin H or other cysteine proteases. (47, 52).  
 
DISCUSSION 
 
Cathelicidin antimicrobial peptides form a distinct family of host defense peptides known to 
share a characteristic gene architecture (1). At the protein level, they are organized in such a way 
that the highly diverse C-terminal antimicrobial domain is attached to the large and highly 
conserved pro-domain known as the cathelin-like domain, which is constrained by two invariant 
disulfide bonds and shows high homology to the cathelin of pig leukocytes (1, 9, 69). The 
structures of C-terminal antimicrobial peptides are highly variable, including short tryptophan-, 
proline-rich or α-helical peptides and β-hairpin peptides stabilized by one or two disulfide bonds. 
Although the exact mechanism of the antimicrobial action of individual CAMPs may vary, they 
all appear to act on microbial membranes. Despite their diverse sizes and structures, nearly all of 
them display a net positive charge and maintain an overall amphipathic character – the common 
features which allow them to attach to and disrupt the negatively charged microbial membranes 
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(1, 8). It is broadly accepted that precursor forms of CAMPs are functionally inactive and require 
proteolytic cleavage to free the C-terminal active peptide (12, 14, 16, 20). Recently, the 
recombinant pro-cathelicidin hCAP18 has been shown to be inactive against a panel of Gram-
positive and Gram-negative bacteria tested in standard radial diffusion and liquid phase AMP 
testing assays (35). In contrast, the mature LL-37 peptide and hCLD demonstrated antibacterial 
activity against distinct spectrums of bacteria (35). We produced full-length pro-cathelicidin 
precursor protein by a recombinant method in E. coli and generated the cathelin-like domain 
protein (hCLD) and the mature LL-37 peptide by cleavage of the precursor holoprotein with the 
in vivo processing enzyme, proteinase 3 (19). The homogeneity and correct folding of 
recombinant proteins were confirmed by detailed ESI-MS and structural studies of hCLD. We 
used recombinant pro-cathelicidin, hCLD and LL-37 proteins in a functional analysis, the results 
of which were distinct from those of Zaiou et al (35) and were in contrast to an earlier prevailing 
view of the relationship between the processing of CAMPs and their function. The precursor 
holoprotein pro-cathelicidin displayed antibacterial activity similar to mature LL-37 against E. 
coli and E. aerogenes tested by the vCC method and E. coli tested by the traditional colony count 
method. The lack of activity against S. aureus suggests that different mechanisms of action exist 
between Gram-positive and Gram-negative bacteria, perhaps in a way similar to defensins (70-
72).  The cathelin-like domain protein, hCLD, lacked any antibacterial function. Taken together, 
our studies demonstrated for the first time that the antibacterial activity against gram negative 
bacteria of the LL-37 cathelicidin is not inhibited by the hCLD pro-region, both intramolecularly 
within the precursor holoprotein, and intermolecularly, since an exogenously added pro-region 
protein had no effect on the bactericidal activity of the mature peptide. In this respect, human 
cathelicidin differs significantly from defensins, for which the processing of inactive precursors 
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was shown to be definitively required for antibacterial function (56, 73, 74). The pro-peptides of 
defensins are anionic, especially in the case of the cryptdins, the family of α-defensins from the 
Paneth cells of the mouse (56, 75). It has been shown that nine N-terminal acidic amino acids of 
pro-cryptdin 4 are primarily responsible for inhibition of the defensin domain (76, 77). Unlike 
the pro-peptides of defensins, the hCLD pro-region has no net charge. Although it has been 
shown for human α-defensin, HNP1 that hydrophobic forces rather than electrostatic interactions 
have a dominant role in mediating the interaction between the anionic pro-peptide and the 
cationic defensins (57), the absence of charge complementarity between the neutral hCLD pro-
region and its cationic LL-37 counterpart should not be overlooked. The lack of electrostatic 
potential may directly determine the low affinity intermolecular binding of the hCLD protein for 
the LL-37 peptide and the lack of intramolecular inhibition of LL-37 activity within the 
precursor protein. Further, whereas pro-defensins have a net neutral charge, the pro-cathelicidin 
precursor preserves the cationicity of the mature LL-37 peptide (+6 net charge). Therefore, if 
cationicity is the most important factor determining the antimicrobial activity of the mature LL-
37 peptide, the unprocessed pro-cathelicidin protein should retain effectiveness.  
Sanchez et al (47) first elucidated the structural basis of interactions between the cathelin-
like domain pro-region and the cathelicidin antimicrobial peptide based on the modeled structure 
of the porcine ProS-PG1 precursor protein. Precursor forms of protregrins were shown 
previously to be inactive against bacteria, requiring cleavage by elastase to perform their 
antimicrobial functions, (78) and the proposed model of the precursor holoprotein fully explains 
the mechanism by which the N-terminal antibacterial peptide is inhibited functionally by its C-
terminal pro-region (47). In contrast to LL-37, which is unstructured in solution and adopts α-
helical structure only in structure-inducing environments such as the presence of SDS (54, 79), 
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PG1 consists of a rigid β-hairpin structure constrained by two disulfide bonds (80). In the 
proposed minimized model of the holoprotein, the PG1 peptide docks as an extension of the 
central β-sheet of ProS and establishes multiple hydrophobic and electrostatic interactions with 
the ProS core. In addition, the high content of anionic residues (17 acidic residues) and the 
negative net charge (-4) of ProS suggest that electrostatic interactions with the positively charged 
antimicrobial peptide are likely. A predicted tight packing of the holoprotein and multiple 
intramolecular interactions between ProS and PG1 has been suggested to be responsible for 
inactivation of the antibacterial precursor (47). A similar model of a compact and well-stabilized 
structure of the holoprotein cannot be easily proposed for the hCLD-LL-37 precursor based on 
the available hCLD structure. In fact, the lack of charge complementarity between hCLD and 
LL-37 and the low intermolecular affinity of the cathelin-like pro-region for the LL-37 peptide 
preclude that a compact conformation would be formed when assembled into a single 
polypeptide chain. A similar susceptibility for degradation in vitro and in vivo in human wound 
fluid by elastase-producing P. aeruginosa has been recently reported for both the mature LL-37 
peptide and the precursor pro-cathelicidin, suggesting that the antimicrobial peptide is not 
protected in the holoprotein from proteolytic degradation in protease-rich environments by the 
cathelin-like platform (3, 81).  Nevertheless, LL-37 is present primarily as the uncleaved 
holoprotein (3) in a variety of locations including wound and blister fluids (82), phagocytic 
vacuoles (19), psoriatic skin (83), and seminal plasma (27).  In this sense, perhaps it is not 
surprising that the pro-cathelicidin is active, since it is so widespread. 
Interestingly, we detected a moderate inhibition of cathepsin L activity in the presence of 
high doses of the precursor pro-cathelicidin holoprotein and the mature LL-37 peptide. The fact 
that the same inhibitory effect is observed for both pro-cathelicidin and LL-37 suggests that the 
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LL-37 peptide part of the precursor, rather than the cathelin-like motif, interacts with the 
cathepsin L active site. Similar results were reported in the early 1990s when the weak inhibition 
of cathepsin L by the precursor forms of bovine cathelicidins ProBac5, ProBac7 and proBMP-28 
was detected (51, 52). These authors suggested that a weak inhibitory activity observed for some 
cathelicidin precursors is functionally irrelevant and may be due to nonspecific interactions that 
block access to the enzyme active site (52). In fact, we confirmed that the LL-37 peptide may 
serve as a cathepsin L substrate (data not shown). 
In conclusion, our results contrast with the commonly held view that cathelicidin 
precursors are unable to display the biological functions of the mature cathelicidin peptide due to 
intramolecular inhibition by the cathelin-like domain pro-region. We limited our functional 
analysis to antibacterial activity testing, so we cannot exclude that the pro-cathelicidin precursor 
holoprotein may also exhibit other biological activities of LL-37, which were initially assigned 
only to the mature peptide. Further studies are required to determine the biological activities of 
pro-cathelicidin and fully analyze the spectrum of functional overlap between LL-37 and its 
precursor protein. Since the CAMP family is highly heterogeneous and covers a wide range of 
structurally distinct peptides, we cannot conclude that observations we made of the precursor 
protein of human cathelicidin could be generalized over all CAMP family members. To the 
contrary, we strongly believe that other family members may undergo functional inactivation 
through interactions with the cathelin-like pro-region in the precursor holoprotein. As an 
example, a cysteine-bridged β-hairpin of porcine protregrin was proposed to dock effectively on 
the cathelin-like motif platform. In this respect, human cathelicidin may be the only exception. It 
would not be the only antimicrobial peptide to be active in the human version in ways that differ 
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from other mammals.  For example, defensins bind and inactivate anthrax lethal factor (71, 84, 
85), and the defensin HD6 self-assembles to form nanonets that trap bacteria (86).  
To this end, the significance of the strong evolutionary pressure for the conservation of 
the cathelin-like pro-region among the CAMP family is still poorly explored and a matter of 
debate. By combined structural and functional studies, we proved that hCLD does not exhibit a 
protease inhibitory function regardless of its overall structural similarity to cystatins. CLDs share 
a common cystatin-like fold with a wide range of distinct proteins which play a variety of roles 
other than protease inhibitory biological functions (47). Although the evolutionary record 
contains only one human CLD among the great diversity of CLDs found in mammals, it appears 
that the cystatin scaffold may represent an ancestral structural platform which has diverged in the 
various species to form proteins both with and without inhibitory functions. 
FIGURES  
Figure 1.  C18 RP-HPLC and ESI-MS analysis of purified recombinant pro-cathelicidin, LL-37 
and hCLD. Proteins were analyzed on a Waters XBridgeTM BEH130 C18 column (4.6 x 150 mm, 
3.5µm) using a linear gradient of 5 – 65% acetonitrile at a flow rate of 1 mL/min over 30 min. 
The experimental values of the molecular masses of the desired products are shown together with 
expected values calculated based on the average isotope compositions (in parentheses). 
Figure 2.  The overall structure of the human cathelin-like domain. (A) The stereoscopic 
representation of the fold of hCLD drawn as a cartoon diagram. Disulfide bonds are depicted as 
yellow balls and sticks. (B) Alignment of hCLD and ProS, the cathelicidin-like domain of the 
pig. A stereo view of the superposition of crystal structures (hCLD in green, ProS in orange) is 
shown at the top of the Figure, with the amino acid sequence alignment at the bottom. Amino 
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acids identical in both sequences are indicated by stars. Topology diagrams depicting a 
distribution of secondary structure elements as calculated with DSSP (87) are shown above the 
aligned sequences and assisted by a plot of the average RMS deviations (in Å) of the 
corresponding Cα positions.  
Figure 3.  Comparison of the crystal structure of hCLD and the solution structure of ProS. Left 
panel: Superposition of Cα ribbon diagrams of hCLD (green) and ProS (pink) Right panel: 90° 
rotated close-up view of the L1 and L2 loop regions. Disulfide bonds and residues of hCLD 
involved in a hydrogen-bonded turn are shown as balls and sticks. 
Figure 4.  Effect of pro-cathelicidin, hCLD and LL-37 on the activity of human cathepsin L. (A) 
Hydrolysis of Z-Phe-Arg-AMC substrate by human liver cathepsin L (0.1 mU) in the presence of 
hCLD (concentration ranging from 0-1,000 nM). Human urine cystatin C at 10 nM concentration 
was used as a positive control. (B) Dose-dependent inhibition of cathepsin L (0.1 mU) by pro-
cathelicidin, hCLD and LL-37 and human urine cystatin C. The remaining activity of cathepsin L 
was measured 20 minutes after the reaction and hydrolysis was initiated by the addition of the Z-
Phe-Arg-AMC substrate. Each curve is the mean of three independent experiments.   
Figure 5.  Antibacterial activity of pro-cathelicidin, hCLD and LL-37 determined by the virtual 
colony count method. Virtual survival curves are shown of (A) E. coli ATCC 25922, (B) E. 
aerogenes ATCC 13048 and (C) S. aureus ATCC 29213 exposed to protein concentrations 
varying twofold from 1-256 μg/mL in triplicate, except hCLD was analyzed in duplicate.  In 
addition, because the E. aerogenes results included a paradoxical point at 256 μg/mL, and 
because the background turbidity in the absence of cells was much greater when pro-cathelicidin 
in phosphate buffer was mixed with 2x Mueller-Hinton broth at 256 μg/mL than at 128 μg/mL or 
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below, pro-cathelicidin was also analyzed in a separate series from 0.5-128 μg/mL.  Some points 
are reported in duplicate (3.6 μM LL-37 vs. both E. coli and E. aerogenes, 18.6 μM HNP1 vs. S. 
aureus) or singly (7.1, 14.2 and 57.0 μM LL-37 vs. S. aureus) because the other replicates were 
scored with threshold times of >720 minutes (virtual survival = 0) in the VCC assay.  Virtual 
survival was also zero for the four highest concentrations tested (7.1-57.0 μM) of LL-37 vs. both 
E. coli and E. aerogenes, and the two highest concentrations of HNP1 (37.2 and 74.4 μM) vs. S. 
aureus and these points could not be plotted on a logarithmic scale. Protein concentrations were 
converted from μg/mL to μM for plotting.  HNP1 was used as positive control. Each curve is the 
mean of three separate experiments (±S.D.). Points scored as zero virtual survival could not be 
plotted. (D) Antibacterial activity of LL-37 in the presence of the hCLD protein. The virtual 
survival curves of E. coli ATCC 25922 are shown in the presence of 1.4 µM LL-37 alone (open 
circle) or titrated with hCLD at concentrations varying twofold from 0.23 to 60 µM (open 
squares). The data are an average of two independent experiments. 
Figure 6.  Structural alignment of hCLD and the cysteine protease inhibitor Cystatin C. 
Backbone atoms of hCLD were superimposed on monomeric human Cystatin C in the 
unliganded state (PDB code: 3GAX). hCLD is shown in green, Cystatin C in yellow and, in both, 
the N-terminus is colored in red. Four additional residues at the N-terminus of hCLD as remnants 
of the cleavage by thrombin are colored in grey. The crystal structure of monomeric human 
cystatin C stabilized against aggregation was chosen for comparison since in all crystal structures 
of Cystatin C studied to date, the protein has been found to form 3D domain-swapped dimers, 
created through a conformational change of a beta-hairpin loop, L1 (68, 88-90). 3D domain 
swapping free structure defines the conformation of loop L1, which is essential for the inhibition 
of papain-like cysteine proteases. 
 25 
Figure 7.  Structural comparison of hCLD and the cysteine protease inhibitor stefin A. (A) 
Backbone atoms of hCLD were superimposed on stefin A in the stefin A-cathepsin H complex 
(PDB code: 1NB5, (67)). hCLD is shown in green, stefin A in blue and cathepsin H in grey. 
Catalytic Cys-25 and His-159 of cathepsin H are shown in yellow and residues of the N-termini 
and hairpin L1 and L2 loops of stefin A with motifs highly conserved among cysteine protease 
inhibitors are shown in light blue. The disordered Pro65 region of the L1 loop is indicated by a 
green dotted line (B) The same as (A) with the cathepsin H surface shown in grey and colored 
yellow around active site residues.  
  
 26 
TABLES.  
Table 1. Crystallographic data collection and refinement statistics 
Data collection  
Wavelength, Ǻ 
Space group 
Cell parameters  
 
Molecules/a.u. 
Resolution, Åa 
Number of reflections 
Total 
Unique 
Rsymb, % 
I/σ 
Completeness, % 
Redundancy 
0.98 
P21212 
a=91.15 Å, b=57.99 Å, c=39.55 Å 
   2 
91.15-1.93 (2.0-1.93) 
 
30982 
16740 
9.8 (37.2) 
14.4 (6.1) 
99.4 (98.7) 
6.2 (6.8) 
Refinement statistics  
Resolution, Å 
Rcrystc, % 
Rfreed, % 
Number of atoms 
Protein 
Water 
Root mean square deviation 
Bond lengths, Å 
Bond angles, °  
Ramachandran plot 
Most favored region, % 
Additional allowed region, % 
Generously allowed region, %  
Disallowed region, %  
PDB code 
20-1.93 
19.1 
24.2 
 
1629 
133 
 
0.02 
2.0 
 
92.3 
7.7 
0.0 
0.0 
4EYC 
aAll data (outer shell). 
bRsym = ∑│I - <I>│/∑I, where I is the observed intensity and <I> is the average intensity 
obtained from multiple observations of symmetry-related reflections after rejections 
cRcryst = ∑║Fo│- k│ Fc║/∑│Fo │, where Fo and Fc are the observed and calculated structure 
factors, respectively 
dRfree = defined by by Brünger (91) 
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CAMP, Cathelicidin antimicrobial peptide; hCLD, human cathelin-like domain; hCAP18, human 
cationic antimicrobial protein, SPR, surface plasmon resonance; RP-HPLC, reversed-phase high-
performance liquid chromatography; ESI-MS, electrospray ionization mass spectrometry; vCC, 
virtual colony count. 
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Table ST1. Virtual colony count antibacterial activities of pro-cathelicidin and LL-37  
 Virtual lethal doses (µM) 
vLD50 vLD90 vLD99 vLD99.9 
Escherichia coli ATCC 25922 
HNP11 0.98 ± 0.11 2.17 ± 0.27 15.71 ± 10.91 26.31 ± 15.43 
LL-37 0.67 ± 0.08 1.30 ± 0.09 Footnote 2 Footnote 3 
hCLD > 21 > 21 > 21 > 21 
proLL-37 16-0.06 1.02 ± 0.02 1.27 ± 0.04 1.75 ± 0.11 2.69 ± 0.09 
proLL-37 8-0.03 1.00 ± 0.03 1.30 ± 0.07 1.84 ± 0.16 2.69 ± 0.14 
Enterobacter aerogenes ATCC 13048 
HNP1 2.36 ± 0.09 10.35 ± 1.61 Footnote 4 > 74 
LL-37 0.71 ± 0.11 1.29 ± 0.04 Footnote 5 Footnote 6 
hCLD > 21 > 21 > 21 > 21 
proLL-37 16-0.06 0.98 ± 0.13 1.43 ± 0.15 2.19 ± 0.29 3.26 ± 0.44 
proLL-37 8-0.03 1.22 ± 0.12 1.71 ± 0.30 2.22 ± 0.29 2.84 ± 0.29 
Staphylococcus aureus ATCC 29213 
HNP1 3.15 ± 1.11 Footnote 7 Footnote 8 Footnote 9 
LL-37 1.24 ± 0.15 1.75 ± 0.15 2.27 ± 0.11 2.87 ± 0.15 
hCLD > 21 > 21 > 21 > 21 
proLL-37 16-0.06 11.99 > 16 > 16 > 16 
proLL-37 8-0.03 > 8 > 8 > 8 > 8 
The virtual LD50 (vLD50), vLD90, vLD99 and vLD99.9 were reported as the tested protein 
concentrations that resulted in survival rates of 0.5, 0.1, 0.01 and 0.001, respectively. The 
values represent an average of three independent experiments, except as follows: against E. 
coli hCLD and the proLL-37 series between 8 and 0.03 µM are in duplicate, and at 3.6 µM 
LL-37 is reported in duplicate, because its threshold time was >720 minutes in the third 
replicate;  against E. aerogenes hCLD is in duplicate, the proLL-37 series between 8 and 0.03 
µM is in duplicate except for 8 µM, which is a single data point because the other replicate 
had a threshold time of >720 minutes, in the proLL-37 series between 16 and 0.06 µM, the 16 
µM is in duplicate because the threshold time of the third replicate was >720 minutes, and at 
3.6 µM LL-37 is reported in duplicate, because its threshold time was >720 minutes in the 
third replicate; against S. aureus hCLD and the proLL-37 series between 8 and 0.03 µM are in 
duplicate, and in two cases single results are reported because at the 7 and 14 µM 
concentrations of LL-37, two assays resulted in threshold times of > 720 minutes and the third 
did not.   
1human α-defensin 1 (HNP1) was used as positive control 
2The three vLD99 values were 1.8 < vLD99 < 3.6, 1.96, and 1.95 
3The three vLD99.9 values were 1.8 < vLD99.9 < 3.6, 2.25, and 2.27. 
4The three vLD99 values were 30.13, >74, and 55.68 
5The three vLD99 values were 2.26, 1.87, and 0.9 < vLD99 < 1.7. 
6The three vLD99.9 values were 3.14, 2.31, and 0.9 < vLD99.9 < 1.7. 
7The three vLD90 values were 9.14, 7.63 and 9.3 < vLD90 < 18.6. 
8The three vLD99 values were 18.6 < vLD99 < 37.2, 10.89, and 9.3 < vLD99 < 18.6. 
9The three vLD99.9 values were 18.6 < vLD99.9 < 37.2, 13.18, and 9.3 < vLD99.9 < 18.6. 
 
 
 
Table ST2. Colony count antibacterial activities of HNP1, LL-37, hCLD and pro-cathelicidin.   
 LD (mM) 
LD50 LD90 
E. coli ATCC 25922 
HNP1 0.12 ± 0.09 > 29 
LL-37 0.21 ± 0.16 0.6 < LD90 < 4 
hCLD > 8 > 8 
pro-cathelicidin 0.52 ± 0.28 1 < LD90 < 6 
S. aureus ATCC 29213 
HNP1 19.0 ± 3.8 > 29 
LL-37 0.6 < LD50 < 4 0.6 < LD90 < 4 
hCLD > 8 > 8 
pro-cathelicidin > 6 > 6 
The LD50 and LD90 were calculated as the tested protein concentration that resulted in survival 
rates of 0.5, and 0.1 respectively in the colony count assay. The values represent an average of 
two independent experiments.  HNP1 was weaker in the colony count assay than the vCC 
assay at high concentrations, in accordance with the fact that vCC reports lag times in 
addition to bacteriostatic activity and bactericidal killing (1) and initial reports of a lack of 
HNP activity at 50 µg/mL in unsupplemented 10 mM sodium phosphate buffer (2).  
Differences between colony count LD50 and vCC vLD50 could reflect an inoculum effect, 
since the concentration of cells exposed to peptides was 20-fold higher for vCC, and 
differences could also reflect that nutrients carried forward from the initial seed culture were 
20-fold more dilute in the colony count assay. 
 
Figure S1. Stereo view of a superposition (A) and its 90° rotation (B) of hCLD molecules 
present in the asymmetric unit of the crystal. Structures can be superimposed with the root 
mean square deviation of equivalent Cα atoms of 0.61 Ǻ.  
  
 
 
 
Figure S2. Antibacterial activity of pro-cathelicidin, hCLD and LL-37 determined by the 
traditional colony count method. Survival curves are shown of (A) E. coli ATCC 25922 and 
(B) S. aureus ATCC 29213 exposed to protein concentrations varying six-fold from 0.013 to 
100 μg/mL in 10 mM sodium phosphate buffer, and converted to μM for plotting. Costar 
3595 96-well plates were used for the 2-hour defensin exposure at 37 ºC and subsequent 50-
to-100-fold dilutions in buffer before spreading on Meuller Hinton agar plates and incubating 
overnight at 30-37 ºC.  2-3 mm diameter colonies were counted and plotted with the standard 
error of the mean for duplicate experiments.  HNP1 was used as positive control. Points 
scored as zero survival, 16.7 and 100 μg/mL (3.7 and 22.3 μM) LL-37 against both E. coli and 
S. aureus and 100 μg/mL (6.1 μM) proLL-37 against E. coli, could not be plotted. 
 
 Figure S3. Anti-E.coli 25922 activity of LL-37, pro-cathelicidin and hCLD as measured 
using a standard radial diffusion assay (3). Clear areas on tryptone/agarose plates indicate 
antibacterial activity causing a decrease in bacterial colony density.  The highest two 
concentrations of LL-37 and pro-cathelicidin are enlarged with red bars showing the relative 
diameters.  LL37 shows antimicrobial activity at 50uM, 25uM and 12.5uM and pro-
cathelicidin at two highest concentrations tested of 50uM and 25 uM. hCLD shows no 
antibacterial activity. The radial diffusion assay was conducted in a different laboratory than 
the virtual colony count assay. 
 Figure S4. Anti-E.coli activity of LL-37, pro-cathelicidin and hCLD as measured using a 
lawn-spotting assay (4). 10ul of serial solutions (0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.125, 6.25, 12.5, 
25, 50uM) of each peptide were spotted on the surface of the bacterial lawn. 5% Acetic Acid 
was used as a positive control. Clear spotted areas indicate antibacterial activity causing a 
decrease in bacterial colony density.  LL37 show obvious antimicrobial activity at 50uM, 
25uM and 12.5uM and pro-cathelicidin at highest concentration tested of 50uM. hCLD shows 
no antibacterial activity in this assay. 
 1. Ericksen, B., Wu, Z., Lu, W., and Lehrer, R. I. (2005) Antibacterial activity and 
specificity of the six human {alpha}-defensins, Antimicrob Agents Chemother 49, 269-
275. 
 
2. Ganz, T., Selsted, M. E., Szklarek, D., Harwig, S. S., Daher, K., Bainton, D. F., and 
Lehrer, R. I. (1985) Defensins. Natural peptide antibiotics of human neutrophils, The 
Journal of clinical investigation 76, 1427-1435. 
 
3. Lehrer, R. I., Rosenman, M., Harwig, S. S., Jackson, R., and Eisenhauer, P. (1991) 
Ultrasensitive assays for endogenous antimicrobial polypeptides, J Immunol Methods 
137, 167-173. 
 
4. Shi, J., Ross, C. R., Leto, T. L., Blecha, F. (1996) PR-39, a proline-rich antibacterial 
peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 
domains of p47 phox. Proc. Natl. Acad. Sci. 11;93(12):6014-8 
 
. 
 
 
 
